摘要
目前,抗体Fab片段在癌症、病毒感染和炎症等疾病的诊断治疗中越发重要,占抗体市场份额逐渐上升。相对于全长抗体,抗体Fab片段具有无须N糖基化、可用原核系统进行表达、分子小、免疫原性低等优势,使之成为研究的热点。大肠杆菌由于遗传背景清晰、使用广泛、生产成本低,因而常作为原核表达宿主。本文综述了大肠杆菌系统抗体Fab片段产量低的解决方法、Fab抗体的临床应用,并结合当前研究现状展望了Fab抗体生产的研究方向。
Currently, antibody fragment Fab play major role in treating a wide variety of human diseases including cancer, viral infection inflammation as well as immune disease. The market of Fab fragment is gradually growing. Compared to full-length antibodies, low molecular weight and low immunogenicity and alternative system of prokaryotic distribute the antibody fragment to hot spot of study. Escherichia coli is chosen to be the host bacteira because of its clear genetic background, extensive use and low production cost. In this review, we highlighted recent significant progress in the engineering of E.coli for enhanced production of functional Fab by overcome some of the limitations of the bacterial production system. We also summraized some clinical application of Fab antibod- ies and proposed some orientation for future research on Fab engineering combined with current research progress.
出处
《生物技术通讯》
CAS
2017年第3期397-404,共8页
Letters in Biotechnology
基金
国家重点基础研究发展计划(2011CBA00800)
